07:00 , Aug 17, 2015 |  BC Week In Review  |  Company News

Biomics Biotechnologies, Benitec deal

Benitec purchased Biomics’ share in DNA-directed RNAi (ddRNAi)-based HBV drug candidate Hepbarna , which the companies had been developing under a JV. Benitec now has exclusive, worldwide rights to develop and commercialize the preclinical product....
08:00 , Feb 28, 2011 |  BC Week In Review  |  Company News

Benitec, Biomics Biotechnologies Co. Ltd. deal

Following the successful identification of over 500 RNA sequences capable of inhibiting viral replication under a 2009 deal to co-develop and commercialize a DNA directed or vector expressed RNAi to treat HBV infection, the companies...
08:00 , Dec 14, 2009 |  BC Week In Review  |  Company News

Biomics Biotechnologies, Zetiq Technologies deal

Biomics received exclusive rights to develop and commercialize Zetiq's CellDetect cervical cancer diagnostic in China for five years. The cell-based in vitro assay that uses color staining to identify tumor cells has completed pilot testing....
07:00 , Sep 14, 2009 |  BC Week In Review  |  Company News

Benitec, Biomics Biotechnologies deal

The companies signed a binding agreement to co-develop and commercialize a DNA directed or vector expressed RNAi to treat HBV infection after a memorandum of understanding between the parties in July. The companies will collaborate...
07:00 , Jul 20, 2009 |  BC Week In Review  |  Company News

Benitec, Biomics Biotechnologies Co. Ltd. deal

The companies signed a memorandum of understanding to co-develop and commercialize a DNA directed or vector expressed RNAi to treat HBV infection. The partners will use Benitec's DNA-directed RNAi (ddRNAi) technology and Biomics' technical platform...